Startpage

  • Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

    GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug…

    by
  • Isofol appoints nomination committee ahead of the Annual General Meeting 2022

    GOTHENBURG, Sweden, November 19, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that…

    by
  • Isofol Medical AB (publ) publishes interim report for January – September 2021

    GOTHENBURG, Sweden, November 11, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report…

    by
  • Trading in Isofol’s shares commences today on Nasdaq Stockholm

    GOTHENBURG, Sweden, October 21, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that…

    by